Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

The Effect of Different Rituximab-Containing Chemotherapy Strategies on Hepatitis C Viremia

Parag Mahale, MBBS, MPH, Francesco Turturro, MD, Jorge Romaguera, MD, Nathan Fowler, MD, Harrys A. Torres, MD FACP

Blood (2014) 124 (21): 4448.

https://doi.org/10.1182/blood.V124.21.4448.4448

Published: 2014

Journal Articles

Development of Non-Hodgkin’s Lymphoma As Second Primary Cancer in Hepatitis C Virus-Infected Patients with a Different Primary Malignancy – a Case Series

Parag Mahale, MBBS, MPH, Jorge Romaguera, MD, Francesco Turturro, MD, Nathan Fowler, MD, Harrys A. Torres, MD FACP

Blood (2014) 124 (21): 5414.

https://doi.org/10.1182/blood.V124.21.5414.5414

Published: 2014

Journal Articles

A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Michelle A. Fanale, MD, Fredrick B. Hagemeister, MD, Luis Fayad, MD, Yasuhiro Oki, MD, Nathan Fowler, MD, Jorge Romaguera, MD, Nina Shah, Hubert Chuang, MD, Lei Feng, MS, Sandra B Horowitz, PharmD, Emily Wesson, APN, Toni Y Hutto, BS, Tariq Muzzafar, MD, Felipe Samaniego, MD, R Eric Davis, MD

Blood (2014) 124 (21): 1744.

https://doi.org/10.1182/blood.V124.21.1744.1744

Published: 2014

Journal Articles

Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience

Preetesh Jain, MD, DM, PhD, Hagop M Kantarjian, MD, Jorge E. Cortes, MD, Elias J. Jabbour, MD, Stefan H. Faderl, MD, William G. Wierda, MD, PhD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, MD, Srdan Verstovsek, MD, PhD, Jan A. Burger, MD, PhD, Luis Fayad, MD, Jorge Romaguera, MD, Rebecca Garris, BSc, Farhad Ravandi, MD, Susan O'Brien, MD, Deborah Thomas, MD

Blood (2013) 122 (21): 3917.

https://doi.org/10.1182/blood.V122.21.3917.3917

Published: 2013

Journal Articles

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

Deborah A. Thomas, MD, Susan O'Brien, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, William G. Wierda, MD, PhD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Alessandra Ferrajoli, MD, Srdan Verstovsek, MD, PhD, Jan A. Burger, MD, PhD, Rebecca Garris, BA, Jorge Romaguera, MD, Fredrick Hagemeister, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 1781.

https://doi.org/10.1182/blood.V116.21.1781.1781

Published: 2010

Journal Articles

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Michelle A. Fanale, MD, Chao-Ming Lai, APN, Peter McLaughlin, MD, Jorge Romaguera, MD, Luis Fayad, MD, Fredrick Hagemeister, MD, Felipe Samaniego, MD, MPH, Maria Alma Rodriguez, MD, Sattva S. Neelapu, Jatin J Shah, MD, Larry Kwak, Wenli Dong, Valerie Reed, MD, Bouthaina S. Dabaja, MD, Uday Popat, MD, Anas Younes, MD

Blood (2010) 116 (21): 2812.

https://doi.org/10.1182/blood.V116.21.2812.2812

Published: 2010

Journal Articles

Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants.

Deborah A. Thomas, MD, Stefan Faderl, MD, Susan O'Brien, MD, William G. Wierda, MD, PhD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, PhD, Marina Konopleva, MD, PhD, Tapan Kadia, MD, Steven M. Kornblau, MD, Luis Fayad, MD, Jorge Romaguera, MD, Jorge E. Cortes, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2831.

https://doi.org/10.1182/blood.V116.21.2831.2831

Published: 2010

Journal Articles

Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma.

Anas Younes, MD, Mark Kirschbaum, MD, Lubomir Sokol, MD, PhD, Lorrin Yee, Jorge Romaguera, MD, Lovely Goyal, Cheng-Pang Hsu, Yuying Hwang, Kevin Gorski, Susan Wong, Darrin M. Beaupre, MD, PhD

Blood (2009) 114 (22): 1708.

https://doi.org/10.1182/blood.V114.22.1708.1708

Published: 2009

Journal Articles

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Saroj Vadhan-Raj, MD, Luis Fayad, MD, Michelle Fanale, M.D., Barbara Pro, Alma Rodriguez, Frederick Hagemeister, Kandice Ames, RN, Carlos E. Bueso-Ramos, MD, Xiao Zhou, MD, PHD, Peter McLaughlin, Nathan Fowler, Jatin Shah, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 105.

https://doi.org/10.1182/blood.V114.22.105.105

Published: 2009

Journal Articles

Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data.

Amanda R Copeland, MS, Yumei Cao, MD, Michelle Fanale, M.D., Luis Fayad, MD, Peter McLaughlin, Barbara Pro, MD, Fredrick Hagemeister, Jorge Romaguera, MD, Felipe Samaniego, MD, Alma Rodriguez, MD, Anas Younes, MD

Blood (2009) 114 (22): 1680.

https://doi.org/10.1182/blood.V114.22.1680.1680

Published: 2009

Journal Articles

Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma.

Anas Younes, MD, Amanda R Copeland, MS, Jorge Romaguera, MD, Luis Fayad, MD, Michelle Fanale, M.D., Silvana de Castro Faria, MD, PhD, L. Jeffrey Medeiros, MD, Ph.D, S. Percy Ivy, MD

Blood (2009) 114 (22): 3744.

https://doi.org/10.1182/blood.V114.22.3744.3744

Published: 2009

Journal Articles

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Anas Younes, MD, Leo Gordon, MD, Stella Kim, MD, Jorge Romaguera, MD, Amanda R Copeland, MS, Silvana de Castro Farial, MD, Larry Kwak, MD, PHD, Luis Fayad, MD, Frederick Hagemeister, MD, Michelle Fanale, M.D., John Lambert, PhD, Teresa Bagulho, MD, Rodica Morariu-Zamfir, MD

Blood (2009) 114 (22): 585.

https://doi.org/10.1182/blood.V114.22.585.585

Published: 2009

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Liang Zhang, PhD, Luis Fayad, MD, Fredrick Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, M.D., Barbara Pro, MD, Anas Younes, MD, Scott Miller, Robert D. Knight, MD, Jerome B. Zeldis, MD, Qing Yi, MD, PhD, Jorge Romaguera, MD

Blood (2008) 112 (11): 3058.

https://doi.org/10.1182/blood.V112.11.3058.3058

Published: 2008

Journal Articles

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Jorge Romaguera, MD, Luis Fayad, Peter McLaughlin, MD, Barbara Pro, MD, Maria Alma Rodriguez, MD, Michael Wang, MD, Pamela Weaver, RN, Kimberly Hartig, Larry Kwak, MD, PhD, Tatyana Feldman, MD, Judy Smith, RN, Peggy Ford, RN, Stuart Goldberg, MD, Andrew Pecora, MD, Andre Goy, MD

Blood (2008) 112 (11): 3051.

https://doi.org/10.1182/blood.V112.11.3051.3051

Published: 2008

Journal Articles

A SCID-hu In Vivo Mouse Model of Human Primary Mantle Cell Lymphoma.

Michael Wang, MD, Yuankai Shi, MD, PhD, Liang Zhang, PhD, Xiaohong Han, MD, Jing Yang, PhD, Jianfei Qian, PhD, Sungyoul Hong, PhD, Pei Lin, MD, Jorge Romaguera, MD, Larry W. Kwak, MD, PhD, Qing Yi, MD, PhD

Blood (2007) 110 (11): 2337.

https://doi.org/10.1182/blood.V110.11.2337.2337

Published: 2007

Journal Articles

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Michael Wang, MD, Luis Fayad, MD, Frederick Hagemeister, MD, Sattva Neelapu, MD, Barry Samuels, MD, Felipe Samanigo, MD, Barbara Pro, MD, Qing Yi, MD, PhD, Neda Bell, Catriona Byrne, Pam Weaver, Kim Hartig, Robert Knight, MD, Jerry Zeldis, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD

Blood (2007) 110 (11): 2562.

https://doi.org/10.1182/blood.V110.11.2562.2562

Published: 2007

Journal Articles

Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy.

Amanda R. Wedgwood, MSN, Michelle A. Fanale, MD, Luis E. Fayad, MD, Peter McLaughlin, MD, Fredrick B. Hagemeister, MD, Barbara Pro, MD, Jorge Romaguera, MD, Maria A. Rodriguez, MD, Felipe Samaniego, MD, Anas Younes, MD

Blood (2007) 110 (11): 215.

https://doi.org/10.1182/blood.V110.11.215.215

Published: 2007

Journal Articles

Trend and Geographic Variations in the Incidence of Mantle Cell Lymphoma in the United States over 30 Years from 1975 to 2004.

Yuhong Zhou, MD, Haijun Wang, MD, Xin Du, MD, PhD, Qing Yi, MD, PhD, Yanxia Zhang, MD, Jorge Romaguera, MD, Michael Wang, MD

Blood (2007) 110 (11): 4414.

https://doi.org/10.1182/blood.V110.11.4414.4414

Published: 2007

Journal Articles

Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL).

Maria Alma Rodriguez, MD, Michelle Fanale, MD, Fredrick Hagemeister, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Romaguera, MD, Larry Kwak, MD, Ph.D., Luis Fayad, MD, Xuelin Huang, Ph.D, Jean Bernard Durand, MD

Blood (2007) 110 (11): 4468.

https://doi.org/10.1182/blood.V110.11.4468.4468

Published: 2007

NARROW

The Effect of Different Rituximab-Containing Chemotherapy Strategies on Hepatitis C Viremia

Development of Non-Hodgkin’s Lymphoma As Second Primary Cancer in Hepatitis C Virus-Infected Patients with a Different Primary Malignancy – a Case Series

A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants.

Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma.

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data.

Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma.

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

A SCID-hu In Vivo Mouse Model of Human Primary Mantle Cell Lymphoma.

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy.

Trend and Geographic Variations in the Incidence of Mantle Cell Lymphoma in the United States over 30 Years from 1975 to 2004.

Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only